Achilles Therapeutics PLCNASDAQ:ACHLNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.0200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.9701/ 3
- Ask / Lots1.0200/ 50
- Open / Previous Close--- / 1.0200
- Day Range---
- 52 Week Range
- Volume110
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACHL |
|---|---|---|
| 09:32 ET | 1000 | 0.975 |
| 09:36 ET | 890 | 0.977 |
| 09:45 ET | 3045 | 0.9764 |
| 10:10 ET | 2131 | 0.9764 |
| 10:12 ET | 100 | 0.9903 |
| 10:14 ET | 100 | 0.9903 |
| 10:24 ET | 100 | 0.9903 |
| 10:26 ET | 1742 | 0.98 |
| 10:33 ET | 100 | 0.9903 |
| 10:39 ET | 3100 | 0.9851 |
| 10:42 ET | 100 | 0.9812 |
| 10:48 ET | 100 | 1 |
| 10:55 ET | 200 | 0.9979 |
| 11:09 ET | 3047 | 0.993 |
| 11:11 ET | 200 | 0.99307 |
| 11:13 ET | 1900 | 0.99305 |
| 11:24 ET | 1000 | 0.993 |
| 11:40 ET | 400 | 0.99 |
| 12:12 ET | 398 | 0.9902 |
| 12:18 ET | 100 | 0.9902 |
| 12:27 ET | 2700 | 0.9882 |
| 12:30 ET | 100 | 0.9931 |
| 12:41 ET | 100 | 1 |
| 01:12 ET | 100 | 1 |
| 01:19 ET | 220 | 0.9857 |
| 01:21 ET | 600 | 0.9856 |
| 01:26 ET | 100 | 1 |
| 01:30 ET | 170 | 0.987 |
| 01:32 ET | 18975 | 0.987 |
| 01:33 ET | 550 | 0.987 |
| 01:42 ET | 101 | 1 |
| 01:44 ET | 100 | 1 |
| 01:46 ET | 12345 | 0.9985 |
| 01:57 ET | 100 | 1.01 |
| 02:06 ET | 100 | 1.01 |
| 02:11 ET | 1659 | 1.01 |
| 02:15 ET | 8000 | 1.01 |
| 02:20 ET | 100 | 1.02 |
| 02:24 ET | 100 | 1.02 |
| 02:27 ET | 100 | 1.02 |
| 02:29 ET | 10000 | 1 |
| 02:33 ET | 100 | 1.01 |
| 02:47 ET | 100 | 1.02 |
| 02:51 ET | 100 | 1.02 |
| 02:56 ET | 100 | 1.02 |
| 02:58 ET | 100 | 1.02 |
| 03:02 ET | 100 | 1.02 |
| 03:05 ET | 100 | 1.02 |
| 03:09 ET | 100 | 1.02 |
| 03:12 ET | 500 | 1.02 |
| 03:16 ET | 100 | 1.02 |
| 03:20 ET | 100 | 1.02 |
| 03:21 ET | 616 | 1.02 |
| 03:25 ET | 100 | 1.02 |
| 03:27 ET | 401 | 1.02 |
| 03:34 ET | 1581 | 1.01 |
| 03:36 ET | 100 | 1.02 |
| 03:38 ET | 819 | 1.02 |
| 03:39 ET | 100 | 1.02 |
| 03:41 ET | 100 | 1.02 |
| 03:43 ET | 100 | 1.02 |
| 03:45 ET | 100 | 1.02 |
| 03:48 ET | 200 | 1.02 |
| 03:50 ET | 100 | 1.02 |
| 03:52 ET | 508 | 1.02 |
| 03:54 ET | 200 | 1.02 |
| 03:56 ET | 200 | 1.02 |
| 03:57 ET | 701 | 1.01 |
| 03:59 ET | 3901 | 1.02 |
Sep 19, 2024
DJ Achilles Therapeutics ADRs Rise 32% on Cost-Cutting Measures, from 10:43AM ET on Thursday Sep 19, 2024 by Dow Jones
10:43AM ET on Thursday Sep 19, 2024 by Dow JonesDJ Achilles Therapeutics to Lay Off Staff as Part of Review, Discontinues Drug Trials, from 7:44AM ET on Thursday Sep 19, 2024 by Dow Jones
7:44AM ET on Thursday Sep 19, 2024 by Dow JonesAchilles Therapeutics Announces Strategic Update, from 7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Achilles Therapeutics PLC | 41.9M | -0.6x | --- |
vTv Therapeutics Inc | 42.7M | -2.1x | --- |
HST Global Inc | 43.2M | -49.8x | --- |
Reviva Pharmaceuticals Holdings, Inc. | 40.4M | -0.9x | --- |
Estrella Immunopharma Inc | 40.2M | -0.6x | --- |
Aeon Biopharma Inc | 43.9M | -0.1x | --- |
Company Information
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.
Contact Information
- Headquarters
- 245 Hammersmith Road, Gunnels Wood RoadLONDON, United Kingdom W6 8PW
- Phone
- 208-154-4600
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Edwin Moses
- Chief Executive Officer, Executive Director
- Iraj Leo Kiryakos Keverian Ali
- Chief Financial Officer
- Robert Coutts
- Chief Scientific Officer
- Sergio Quezada
- Chief Medical Officer
- Karl Peggs
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $41.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 41.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.34 |
EPS | $-1.59 |
Book Value | $3.47 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
